



## Shareholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting

CAMBRIDGE, Mass., May 13, 2010 (BUSINESS WIRE) -- [Vertex Pharmaceuticals Incorporated](#) (Nasdaq: VRTX) today announced results of the voting at its 2010 Annual Meeting of Shareholders.

At the meeting, shareholders re-elected director nominees Dr. Joshua Boger, Dr. Charles A. Sanders and Elaine S. Ullian. Their terms will expire at the 2013 Annual Meeting of Shareholders. Additionally, Dr. Roger W. Brimblecombe announced his retirement from Vertex's Board of Directors effective today.

"As a long-standing member of our Board, Roger provided invaluable insight to Vertex over the past 17 years," said Matthew Emmens, Vertex's Chairman, President and Chief Executive Officer. "I thank Roger for his tireless efforts to advance Vertex throughout his Board tenure, and I wish him well."

Also at today's Annual Meeting, Vertex shareholders approved the amendment to Vertex's Amended and Restated 2006 Stock and Option Plan, increasing by 12.0 million the number of shares of common stock authorized for issuance under the Plan. Shareholders also ratified the selection of Ernst & Young LLP to serve as Vertex's independent registered public accounting firm for the year ending December 31, 2010.

### About Vertex

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, epilepsy, cancer, and pain.

Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.

Lexiva is a registered trademark of the GlaxoSmithKline group of companies.

Vertex's press releases are available at [www.vrtx.com](http://www.vrtx.com).

(VRTX-GEN)

SOURCE: Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

Investors:

Michael Partridge, 617-444-6108

or

Lora Pike, 617-444-6755

or

Media:

Zachry Barber, 617-444-6470

Copyright Business Wire 2010